Creatine for Parkinson's disease - Wikidata - awgldk - TriplyDB

Creatine for Parkinson's disease

Creatine for Parkinson's disease

http://www.wikidata.org/entity/Q24193947

about

The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials

P2860

Q33760040-6296EB93-7647-44FC-BF21-839372814445

P2860

Creatine for Parkinson's disease

http://www.wikidata.org/entity/Q24193947

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Creatine for Parkinson's disease

@ast

Creatine for Parkinson's disease

@en

Creatine for Parkinson's disease

@en-gb

Creatine for Parkinson's disease

@nl

type

label

Creatine for Parkinson's disease

@ast

Creatine for Parkinson's disease

@en

Creatine for Parkinson's disease

@en-gb

Creatine for Parkinson's disease

@nl

prefLabel

Creatine for Parkinson's disease

@ast

Creatine for Parkinson's disease

@en

Creatine for Parkinson's disease

@en-gb

Creatine for Parkinson's disease

@nl

P1433

Q24193947-B043F4E1-2C95-4971-987B-9C6A22258105

P1476

Q24193947-09FA8FA7-7359-4F46-9397-3858EA03F2B0

P2093

Q24193947-208DCB92-0408-4586-8B16-3DAB78BF3242

Q24193947-6E58A3A6-1CFD-4482-A573-EF7797A0D359

Q24193947-73B612B6-B847-45C7-9F83-0ED39FD3BB5C

Q24193947-EB4A9FF9-748E-46C6-A5F0-D2C472FB36A9

P2860

Q24193947-03A6BC12-5AAD-495C-BC45-57189B6D8EF0

Q24193947-0F2E2025-6613-4DFF-94BF-7263ABCAAFED

Q24193947-2AB25199-A345-4037-AF20-E30C38C53591

Q24193947-3843CBCD-1743-431B-B3F8-91910BBBD926

Q24193947-41F9F96A-0DF1-4E9B-846C-ED3DE5249DC7

Q24193947-48EA5A43-F7D1-4DAB-B044-DD1FE472FB6F

Q24193947-4FD22210-1AE4-4F98-A210-7B13589F2DCD

Q24193947-535B9871-3C00-41F8-9B01-3259AE42030F

Q24193947-55033461-3D17-47D8-8467-C7088FF15C65

Q24193947-572E19AA-51EE-421E-8521-D5BC441174C5

P31

Q24193947-07F85D0C-027F-4F58-8BC2-A210DE3785C8

Q24193947-ad060f62-c8c3-4a7e-8d3b-e5e476f1b6ca

P356

Q24193947-115E0ABA-1EB3-49B7-9A05-9C8696844A35

P577

Q24193947-C17B3D10-8436-42BC-8901-19DCBFCC89AE

P698

Q24193947-8ECF96D8-57C4-4FB4-8EDB-D5AE15933508

P921

Q24193947-8C699B65-0572-4C7E-B8F8-9D26C1A9113E

P356

14651858.CD009646.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Creatine for Parkinson's disease

@en

P2093

Hongye Luo

http://www.w3.org/2001/XMLSchema#string

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Man Luo

http://www.w3.org/2001/XMLSchema#string

Yousheng Xiao

http://www.w3.org/2001/XMLSchema#string

P2860

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Parkinson's disease

Epidemiology of Parkinson's disease

Parkinson's disease

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

P31

scholarly article

P356

10.1002/14651858.CD009646.PUB2

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24934384

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease